Next Article in Journal
CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells
Next Article in Special Issue
Vitamin D and Endometrium: A Systematic Review of a Neglected Area of Research
Previous Article in Journal
Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus
Previous Article in Special Issue
Direct Cell–Cell Interactions in the Endometrium and in Endometrial Pathophysiology
Open AccessReview

Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology

1
Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (Oncomet), CIBERONC, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
2
Translational Medical Oncology Group (Oncomet), CIBERONC, Health Research Institute of Santiago (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(8), 2311; https://doi.org/10.3390/ijms19082311
Received: 15 June 2018 / Revised: 24 July 2018 / Accepted: 2 August 2018 / Published: 7 August 2018
(This article belongs to the Special Issue Molecular Research of Endometrial Pathophysiology)
The identification of new molecular targets and biomarkers associated with high risk of recurrence and response to therapy represents one of the main clinical challenges in the management of advanced disease in endometrial cancer. In this sense, the field of liquid biopsy has emerged as a great revolution in oncology and is considered “the way” to reach personalised medicine. In this review, we discuss the promising but already relatively limited advances of liquid biopsy in endometrial cancer compared to other types of tumours like breast, colorectal or prostate cancer. We present recent data analysing circulating tumour material in minimally-invasive blood samples, but also in alternative forms of liquid biopsy like uterine aspirates. Proteomic and genomic studies focused on liquid-based uterine samples are resulting not only in optimal diagnostic tools but also in reliable approaches to address tumour heterogeneity. Likewise, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) represent an opportunity for the correct stratification of patients, for the assessment of early recurrent disease or for the real-time monitoring of therapy responses. Appropriately designed studies and implementation in clinical trials will determine the value of liquid biopsy for precision oncology in endometrial cancer. View Full-Text
Keywords: liquid biopsy; uterine aspirate; circulating tumour cells (CTCs); circulating tumour DNA (ctDNA); exosomes liquid biopsy; uterine aspirate; circulating tumour cells (CTCs); circulating tumour DNA (ctDNA); exosomes
Show Figures

Figure 1

MDPI and ACS Style

Muinelo-Romay, L.; Casas-Arozamena, C.; Abal, M. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology. Int. J. Mol. Sci. 2018, 19, 2311. https://doi.org/10.3390/ijms19082311

AMA Style

Muinelo-Romay L, Casas-Arozamena C, Abal M. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology. International Journal of Molecular Sciences. 2018; 19(8):2311. https://doi.org/10.3390/ijms19082311

Chicago/Turabian Style

Muinelo-Romay, Laura; Casas-Arozamena, Carlos; Abal, Miguel. 2018. "Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology" Int. J. Mol. Sci. 19, no. 8: 2311. https://doi.org/10.3390/ijms19082311

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop